Novartis (VTX:NOVN) has been given a CHF 91 price target by investment analysts at JPMorgan Chase & Co. in a research report issued on Thursday, Borsen Zeitung reports. The firm presently has a “sell” rating on the stock.
Several other equities research analysts also recently issued reports on NOVN. Credit Suisse Group set a CHF 96 price objective on Novartis and gave the stock a “neutral” rating in a report on Thursday. Deutsche Bank set a CHF 96 price objective on Novartis and gave the stock a “neutral” rating in a report on Thursday, January 9th. Barclays set a CHF 85 price objective on Novartis and gave the stock a “sell” rating in a report on Thursday. Goldman Sachs Group set a CHF 105 price objective on Novartis and gave the stock a “buy” rating in a report on Monday, December 16th. Finally, HSBC set a CHF 86 price objective on Novartis and gave the stock a “neutral” rating in a report on Tuesday, November 26th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of CHF 94.27.
Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.